{"id":1012214,"date":"2026-10-21T16:03:23","date_gmt":"2026-10-21T20:03:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/"},"modified":"2026-10-21T16:03:23","modified_gmt":"2026-10-21T20:03:23","slug":"cytokinetics-to-announce-third-quarter-results-on-november-4-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/","title":{"rendered":"Cytokinetics to Announce Third Quarter Results on November 4, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SOUTH SAN FRANCISCO, Calif., Oct.  21, 2026  (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics\u2019 senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.<\/p>\n<p align=\"justify\">The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HDhsVf3GVGv2MyKmQTHLPfuetvCRoD3CNviCOMGRF9idtraEd6iH3GdqmWTmJWPMeaTAmB7vn0pkaXDH7r66Ei4pxDka9OdBnFgz6v-rSZE=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a> or directly at the following link: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NNTos06mQJFtRu6Zb_2K49aJxJgE1jYh6JQ3DHjyy_8LmmbxhF4zWJM11eteauT3qL_kjD4LPKtfb4XUOi8qiLXYdiqyY7nYeA9KrH3j9L0EkG5U4Ok3QupWp13KhhLwfR7Liexspw8hXGrUNOdJJUXhpm3l3sCa4JZA5b8ei8w=\" rel=\"nofollow\" target=\"_blank\">Cytokinetics Q3 2026 Earnings Conference Call<\/a>. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months.<\/p>\n<p align=\"justify\">\n        <strong>About Cytokinetics <\/strong>\n      <\/p>\n<p align=\"justify\">Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics\u2019 MYQORZO<sup>\u00ae<\/sup> (<em>aficamten<\/em>) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of <em>aficamten<\/em> in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing <em>omecamtiv mecarbil<\/em>, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and <em>ulacamten<\/em>, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.<\/p>\n<p>For additional information about Cytokinetics, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HDhsVf3GVGv2MyKmQTHLPfuetvCRoD3CNviCOMGRF9g9djwsgU96f19E8I6EX_fo793Nt3PlM4XUkESFITcyte3ymmK4tfpdjcp2n73Q2XE=\" rel=\"nofollow\" target=\"_blank\">www.cytokinetics.com<\/a>\u00a0and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LrpfTRD4_eTO23PwC56dNErymg0433maqZK5_mCUsksCLq1var3Gw4lDAzifvUeP-bxI7Ob-7dGuM-m3Z2SEoA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sYlpQnXOD5h2sm-VQfmkJieFha14T2Tuv-Qdt4P0I5y682Hzt4hXDwZ5SoXE175nbhtDxMEQgzeC_j5jP-DGXAPGYsng6mlY1G8y21ISgxkX0ZDClzASQsm09R6PZ8Wc\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ahqyW8C_AW_M9gDQL3otVXcMrQltl7KzbtOVCHJ_cPkq-MowjwlnJFDj-lFA6gC7rxl_UK6L-N34QXJuPFKszaF0QMfIFQFuNvZgjKvc6jM=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UoRGOaz-38g6rMSSZ3hPdN-WOXz1Ttam9LqO4hd69S5-afE-sBynQRaBoyDlLk3j-nTtaELWovupb5e2qMik3y5RJtdYbAAxjrO2mHKLJSdFxUqJEu61G-kJbkBua5v8\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Disclaimer<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Omecamtiv mecarbil <\/em>and<em> ulacamten\u00a0<\/em>are investigational medicines. They\u00a0have not been approved\u00a0nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the \u201cAct\u201d). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act\u2019s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics\u2019 and its partners\u2019 research and development activities of Cytokinetics\u2019 product candidates. Such statements are based on management\u2019s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics\u2019 business outlines in Cytokinetics\u2019 filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics\u2019 actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p align=\"justify\">CYTOKINETICS\u00ae and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.<\/p>\n<p align=\"justify\">MYQORZO\u00ae is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.<\/p>\n<p align=\"justify\">Contact:<br \/>Cytokinetics <br \/>Diane Weiser<br \/>Senior Vice President, Corporate Affairs<br \/>(415) 290-7757<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2RlM2I0NDctM2IwNi00ZjRhLThhNDMtOWExZDMyZDAyMDlkLTEwMTY2NzYtMjAyNi0xMC0yMS1lbg==\/tiny\/Cytokinetics-Incorporated.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics\u2019 senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cytokinetics to Announce Third Quarter Results on November 4, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012214","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cytokinetics to Announce Third Quarter Results on November 4, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cytokinetics to Announce Third Quarter Results on November 4, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics\u2019 senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over &hellip; Continue reading &quot;Cytokinetics to Announce Third Quarter Results on November 4, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-21T20:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cytokinetics to Announce Third Quarter Results on November 4, 2026\",\"datePublished\":\"2026-10-21T20:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/\"},\"wordCount\":558,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/\",\"name\":\"Cytokinetics to Announce Third Quarter Results on November 4, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=\",\"datePublished\":\"2026-10-21T20:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cytokinetics to Announce Third Quarter Results on November 4, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cytokinetics to Announce Third Quarter Results on November 4, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/","og_locale":"en_US","og_type":"article","og_title":"Cytokinetics to Announce Third Quarter Results on November 4, 2026 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) &#8212; Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics\u2019 senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors &amp; Media section of Cytokinetics\u2019 website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics\u2019 website for six months. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over &hellip; Continue reading \"Cytokinetics to Announce Third Quarter Results on November 4, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-21T20:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cytokinetics to Announce Third Quarter Results on November 4, 2026","datePublished":"2026-10-21T20:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/"},"wordCount":558,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/","name":"Cytokinetics to Announce Third Quarter Results on November 4, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=","datePublished":"2026-10-21T20:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDY3MiM3OTA5NDgyIzIwMDUxMDM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cytokinetics-to-announce-third-quarter-results-on-november-4-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cytokinetics to Announce Third Quarter Results on November 4, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012214"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012214\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}